{
  "metadata": {
    "start_time": "2025-06-20T01:41:46.971122",
    "mode": "quick",
    "gpu_info": {
      "gpu_count": 1,
      "current_device": 0,
      "gpu_name": "NVIDIA GeForce RTX 4090",
      "gpu_memory_gb": 23.64288330078125,
      "cuda_version": "11.8",
      "platform": "Local"
    },
    "benchmarks": [
      "mirage",
      "medreason",
      "pubmedqa",
      "msmarco"
    ],
    "models": [
      "hierarchical_system"
    ],
    "end_time": "2025-06-20T01:43:33.311532",
    "total_duration_seconds": 106.34041
  },
  "results": {
    "mirage": {
      "benchmark_name": "mirage",
      "start_time": "2025-06-20T01:41:47.104743",
      "models": {
        "hierarchical_system": {
          "results": {
            "model_name": "unknown_model",
            "benchmark_name": "mirage",
            "evaluation_time": 26.79835057258606,
            "total_questions": 10,
            "successful_evaluations": 10,
            "metrics": {
              "total_questions": 10,
              "average_score": 49.92865301673419,
              "accuracy": 0.0,
              "correct_answers": 0,
              "benchmark_name": "mirage"
            },
            "individual_results": [
              {
                "question_id": "mirage_0297",
                "question_type": "clinical",
                "score": 47.18181818181818,
                "correct": false,
                "metrics": {
                  "similarity_score": 0.07954545454545454,
                  "medical_accuracy": 0.8,
                  "clinical_relevance": 0.5,
                  "research_quality": 1.0
                },
                "response": " Based on the presented pattern recognition and hypothesis testing, it appears that the patient may be experiencing an Acute Coronary Syndrome (ACS). The preferred first-line therapy for ACS is dual antiplatelet therapy (Aspirin + P2Y12 inhibitor) as supported by robust clinical trial evidence and major international guidelines. Therefore, the most likely diagnosis is an Acute Coronary Syndrome, specifically angina pectoris or myocardial infarction. However, further diagnostic tests such as ECG, cardiac enzymes, stress testing, or cardiac imaging will be required to confirm the diagnosis and determine the best course of treatment. It is crucial to prioritize patient safety and ensure timely intervention for optimal outcomes.",
                "ground_truth": "Acute coronary syndrome should be considered given the presentation of chest pain and dyspnea.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "mirage_0298",
                "question_type": "clinical",
                "score": 50.806451612903224,
                "correct": false,
                "metrics": {
                  "similarity_score": 0.14516129032258066,
                  "medical_accuracy": 1.0,
                  "clinical_relevance": 0.25,
                  "research_quality": 1.0
                },
                "response": " The first-line treatment for Type 2 Diabetes Mellitus is Metformin, based on robust clinical trial evidence demonstrating significant improvements in patient outcomes including reduced mortality and cardiovascular events. This recommendation is supported by multiple studies such as UKPDS, ADOPT, Cochrane meta-analyses, and ADA/EASD guidelines. Additionally, the efficacy of Metformin has been demonstrated through numerous clinical success stories that show significant reductions in cardiovascular events and improved glycemic control.",
                "ground_truth": "Metformin is the first-line pharmacological treatment for type 2 diabetes mellitus.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "mirage_0299",
                "question_type": "clinical",
                "score": 46.0,
                "correct": false,
                "metrics": {
                  "similarity_score": 0.05,
                  "medical_accuracy": 0.8,
                  "clinical_relevance": 0.5,
                  "research_quality": 1.0
                },
                "response": " Risk factors for developing essential hypertension include:\n\n1. Age: Hypertension is more common in older adults, with a higher prevalence after the age of 30.\n2. Family History: If a close relative (parent, brother, or sister) has had high blood pressure, there is an increased risk of developing it.\n3. Race/Ethnicity: African Americans, Mexican Americans, and some Asian populations are at higher risk.\n4. Obesity: Excess weight and obesity contribute significantly to the development of hypertension.\n5. Poor Diet: Consuming a diet high in salt (sodium), saturated fats, and cholesterol can increase the risk.\n6. Lack of Physical Activity: Regular physical activity helps maintain a healthy weight and reduce blood pressure levels.\n7. Excessive Alcohol Consumption: Drinking more than two alcoholic drinks per day may contribute to high blood pressure.\n8. Tobacco Use: Smoking cigarettes damages the lining of your arteries, making it harder for blood to flow smoothly, thus increasing blood pressure.\n9. Chronic Kidney Disease: The kidneys control your body's fluid balance, and chronic kidney disease can interfere with this process, leading to high blood pressure.\n10. Diabetes Mellitus: Having diabetes increases the risk of developing hypertension.\n11. High Sodium Intake: Consuming more than 2,300 milligrams (mg) a day of sodium can raise blood pressure.\n12. Stress: Chronic stress can affect your heart rate and blood pressure levels.\n13. Sleep Apnea: Obstructive sleep apnea, a condition in which you have brief interruptions of breathing during sleep, increases the risk of hypertension.\n14. Hormonal Changes: In women, hormonal changes during pregnancy (preeclampsia) or menopause can lead to high blood pressure.",
                "ground_truth": "Risk factors include age, family history, obesity, high sodium intake, physical inactivity, and excessive alcohol consumption.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "mirage_0297",
                "question_type": "clinical",
                "score": 56.75862068965517,
                "correct": false,
                "metrics": {
                  "similarity_score": 0.06896551724137931,
                  "medical_accuracy": 0.8,
                  "clinical_relevance": 1.0,
                  "research_quality": 1.0
                },
                "response": " Based on the presented symptoms (chest pain and shortness of breath), the most likely diagnosis is Acute Coronary Syndrome (ACS). The hierarchical diagnostic reasoning follows the three-tier approach as follows:\n\nTIER 1 - PATTERN RECOGNITION:\nThe pattern matched with the presented symptoms corresponds to Pattern 1, which includes ACS. ACS is a common presentation of coronary artery disease and is associated with a rapid onset of symptoms such as chest pain or discomfort, shortness of breath, and other signs and symptoms related to myocardial ischemia or infarction.\n\nTIER 2 - HYPOTHESIS TESTING:\nThe hypothesis was tested using the evidence-based reasoning chain from CURE, TRITON-TIMI, PLATO trials, and ESC/AHA guidelines. The clinical recommendation for ACS is dual antiplatelet therapy (Aspirin + P2Y12 inhibitor) as the preferred first-line therapy.\n\nTIER 3 - CONFIRMATION:\nThe diagnosis was confirmed with comprehensive clinical evidence from multiple sources, including three clinical success stories demonstrating the benefits of guideline-directed medical therapy for heart failure with reduced ejection fraction (HF-REF). The HF-REF cases were treated with ACE inhibitors, beta-blockers, and diuretics, leading to improved survival, reduced hospitalizations, and improved NYHA class.\n\nFinal Diagnostic Response: Based on the presented symptoms and hierarchical diagnostic reasoning, the most likely diagnosis is Acute Coronary Syndrome (ACS). Immediate management should involve dual antiplatelet therapy (Aspirin + P2Y12 inhibitor) as well as other supportive measures. The patient's condition warrants further investigation and monitoring for potential complications.",
                "ground_truth": "Acute coronary syndrome should be considered given the presentation of chest pain and dyspnea.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "mirage_0298",
                "question_type": "clinical",
                "score": 50.21739130434783,
                "correct": false,
                "metrics": {
                  "similarity_score": 0.13043478260869565,
                  "medical_accuracy": 1.0,
                  "clinical_relevance": 0.25,
                  "research_quality": 1.0
                },
                "response": " Based on the pattern recognition, hypothesis testing, and confirmation processes, the first-line treatment for Type 2 Diabetes Mellitus is Metformin. This recommendation is supported by robust clinical trial evidence demonstrating significant improvements in patient outcomes, including reduced mortality, as seen in studies like UKPDS, ADOPT, Cochrane meta-analyses, and ADA/EASD guidelines. The effectiveness of Metformin is further substantiated by numerous clinical success stories that show significant reductions in cardiovascular events and improved glycemic control when combined with lifestyle modifications.",
                "ground_truth": "Metformin is the first-line pharmacological treatment for type 2 diabetes mellitus.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "mirage_0299",
                "question_type": "clinical",
                "score": 50.7877094972067,
                "correct": false,
                "metrics": {
                  "similarity_score": 0.0446927374301676,
                  "medical_accuracy": 0.8,
                  "clinical_relevance": 0.75,
                  "research_quality": 1.0
                },
                "response": " Risk factors for developing hypertension include:\n\n1. Age: Hypertension is more common in older adults, though it can occur at any age.\n2. Family History: If a close relative (parent, brother, sister) has had high blood pressure, you may have an increased risk.\n3. Race: Certain races, including African Americans, are more likely to develop hypertension.\n4. Obesity: Excess weight, especially if you carry it around your waist, can increase your chances of developing high blood pressure.\n5. Lack of Physical Activity: People who are inactive have a greater chance of developing high blood pressure.\n6. Diet: Too much sodium (salt) or too little potassium in your diet can contribute to high blood pressure.\n7. Alcohol Consumption: Drinking more than 2 alcoholic drinks per day for men and 1 drink for women may affect blood pressure by causing your kidneys to retain salt and water.\n8. Tobacco Use: Smoking or being around secondhand smoke can increase both your systolic and diastolic blood pressure.\n9. Chronic Kidney Disease: Damage to your kidneys from diabetes or other causes can lead to high blood pressure.\n10. High Stress Levels: Long-term stress may affect your blood pressure.\n11. Diabetes: Diabetes increases your risk of developing high blood pressure, and high blood pressure is a major complication of diabetes.\n12. Chronic Kidney Disease (CKD): Persistent high blood pressure can cause damage to the small blood vessels in your kidneys, leading to CKD.\n13. Sleep Apnea: This disorder causes breathing interruptions during sleep and is associated with higher blood pressure levels.\n14. Genetic Factors: Some people inherit a predisposition for high blood pressure from their families.",
                "ground_truth": "Risk factors include age, family history, obesity, high sodium intake, physical inactivity, and excessive alcohol consumption.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "mirage_0297",
                "question_type": "clinical",
                "score": 46.72727272727273,
                "correct": false,
                "metrics": {
                  "similarity_score": 0.06818181818181818,
                  "medical_accuracy": 0.8,
                  "clinical_relevance": 0.5,
                  "research_quality": 1.0
                },
                "response": " Based on the presented symptoms (chest pain and shortness of breath), the most likely diagnosis could be Acute Coronary Syndrome (ACS). This is a pattern that matches with several clinical guidelines recommending Dual antiplatelet therapy (Aspirin + P2Y12 inhibitor) as the preferred first-line therapy for ACS. The evidence base includes robust clinical trial evidence demonstrating significant improvements in patient outcomes, such as the CURE, TRITON-TIMI, PLATO trials, and ESC/AHA guidelines.\n\nHowever, to confirm this diagnosis, further diagnostic tests (such as ECG, cardiac enzymes, stress test, or cardiac imaging) should be conducted for a definitive diagnosis and treatment plan. It is crucial to consider all the possible differential diagnoses and rule them out based on the clinical presentation, medical history, physical examination findings, and test results.\n\nFor heart failure with reduced ejection fraction, if it is suspected as a secondary complication of ACS, guideline-directed medical therapy (ACE-I + Beta-blocker + Diuretic) would be an appropriate treatment option. The evidence of its effectiveness includes improved survival rates and reduced hospitalizations, as demonstrated in multiple clinical success stories.",
                "ground_truth": "Acute coronary syndrome should be considered given the presentation of chest pain and dyspnea.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "mirage_0298",
                "question_type": "clinical",
                "score": 51.53061224489795,
                "correct": false,
                "metrics": {
                  "similarity_score": 0.16326530612244897,
                  "medical_accuracy": 1.0,
                  "clinical_relevance": 0.25,
                  "research_quality": 1.0
                },
                "response": " Based on the pattern recognition, hypothesis testing, and confirmation of comprehensive medical knowledge, the first-line treatment for Type 2 Diabetes Mellitus is Metformin. The evidence-based reasoning supports this diagnosis with robust clinical trial evidence demonstrating significant improvements in patient outcomes including reduced mortality, cardiovascular events, and improved glycemic control.",
                "ground_truth": "Metformin is the first-line pharmacological treatment for type 2 diabetes mellitus.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "mirage_0299",
                "question_type": "clinical",
                "score": 47.05084745762712,
                "correct": false,
                "metrics": {
                  "similarity_score": 0.07627118644067797,
                  "medical_accuracy": 0.8,
                  "clinical_relevance": 0.5,
                  "research_quality": 1.0
                },
                "response": " Risk factors for developing hypertension include:\n\n1. Age: Hypertension is more common in older adults, with the risk increasing with age.\n\n2. Genetics: Family history and genetics play a role in the development of hypertension.\n\n3. Lifestyle: Factors such as high-salt diet, obesity, physical inactivity, excessive alcohol consumption, and tobacco use can increase the risk of hypertension.\n\n4. Comorbidities: Conditions like diabetes, kidney disease, sleep apnea, and hyperthyroidism can contribute to the development of hypertension.\n\n5. Race/Ethnicity: Certain racial and ethnic groups have a higher risk of developing hypertension, such as African Americans, Mexican Americans, and Native Americans.\n\n6. Gender: Men are more likely to develop hypertension than women, but the gap narrows after menopause.\n\n7. Geographical Location: Individuals living in urban areas or at higher altitudes may have a higher risk of developing hypertension.\n\n8. Psychological Stress: Chronic stress can contribute to the development and maintenance of hypertension.\n\n9. Environmental Factors: Exposure to air pollution, noise pollution, and other environmental toxins can increase the risk of hypertension.",
                "ground_truth": "Risk factors include age, family history, obesity, high sodium intake, physical inactivity, and excessive alcohol consumption.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "mirage_0297",
                "question_type": "clinical",
                "score": 52.2258064516129,
                "correct": false,
                "metrics": {
                  "similarity_score": 0.08064516129032258,
                  "medical_accuracy": 0.8,
                  "clinical_relevance": 0.75,
                  "research_quality": 1.0
                },
                "response": " Based on the presented symptoms (chest pain and shortness of breath), the most likely diagnosis in this case could be an Acute Coronary Syndrome (ACS). This diagnosis aligns with several patterns identified from major international guidelines, which recommend dual antiplatelet therapy (Aspirin + P2Y12 inhibitor) as the preferred first-line therapy for ACS.\n\nHowever, to confirm the diagnosis and rule out other potential causes of chest pain and shortness of breath, additional information and diagnostic tests would be required. For instance, an electrocardiogram (ECG), cardiac enzymes, and imaging studies like echocardiography or coronary angiography could provide valuable insights into the patient's condition.\n\nFurthermore, it is essential to consider other possible causes of chest pain and shortness of breath, such as pulmonary embolism, pneumonia, or anxiety disorders. These conditions should be ruled out through appropriate diagnostic tests and examinations.\n\nIn summary, while the most likely diagnosis appears to be an Acute Coronary Syndrome based on the presented symptoms and clinical guidelines, further evaluation is necessary for a definitive diagnosis and treatment plan. Always prioritize patient safety and consult with relevant healthcare professionals for comprehensive care.",
                "ground_truth": "Acute coronary syndrome should be considered given the presentation of chest pain and dyspnea.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              }
            ],
            "status": "completed"
          },
          "evaluation_time_seconds": 26.800062,
          "gpu_stats": {
            "allocated_gb": 0.09,
            "reserved_gb": 0.1,
            "total_gb": 23.64,
            "utilization_percent": 0.4
          }
        }
      },
      "end_time": "2025-06-20T01:42:14.087604"
    },
    "medreason": {
      "benchmark_name": "medreason",
      "start_time": "2025-06-20T01:42:14.089128",
      "models": {
        "hierarchical_system": {
          "results": {
            "model_name": "unknown_model",
            "benchmark_name": "medreason",
            "evaluation_time": 27.806978702545166,
            "total_questions": 10,
            "successful_evaluations": 10,
            "metrics": {
              "total_questions": 10,
              "average_score": 28.744704916449344,
              "accuracy": 0.0,
              "correct_answers": 0,
              "benchmark_name": "medreason"
            },
            "individual_results": [
              {
                "question_id": "unknown",
                "specialty": "general",
                "score": 17.32183908045977,
                "correct": false,
                "metrics": {
                  "reasoning_depth": 0.0,
                  "medical_accuracy": 0.15517241379310345,
                  "clinical_workflow": 0.3333333333333333,
                  "specialty_knowledge": 0.6
                },
                "response": " Based on the available information, this assistant does not have sufficient knowledge to provide a definitive answer regarding the percentage of patients with disseminated discoid lupus erythematosus who develop Systemic Lupus Erythematosus (SLE). However, it is known that around 10-30% of patients with cutaneous lupus will eventually develop systemic lupus. It's important to note that individual patient outcomes can vary widely, and a definitive diagnosis and treatment plan should be determined by a healthcare professional based on the specific clinical presentation and laboratory results.",
                "expected_reasoning": [],
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "unknown",
                "specialty": "general",
                "score": 25.066666666666666,
                "correct": false,
                "metrics": {
                  "reasoning_depth": 0.31,
                  "medical_accuracy": 0.0,
                  "clinical_workflow": 0.3333333333333333,
                  "specialty_knowledge": 0.6
                },
                "response": " Based on the presented symptoms and considering the possibility of a urinary tract infection (UTI) given the increased urinary frequency, urgency, and distress, it is crucial to first rule out UTI as a potential cause. The patient's history of rheumatoid arthritis using methotrexate might also indicate the need for renal function evaluation due to the potential nephrotoxicity of this medication.\n\n1. TIER 1 - PATTERN RECOGNITION:\n   - Pattern 9: Urinary Symptoms (Increased frequency, urgency)\n   - Pattern 10: Nephrotoxic Medications (Methotrexate)\n\n2. TIER 2 - HYPOTHESIS TESTING:\n   - Hypothesis 6: UTI\n     - First-line evidence-based treatment: Antibiotics appropriate for UTIs, urine culture and sensitivity testing\n   - Hypothesis 7: Kidney dysfunction due to methotrexate toxicity\n     - First-line evidence-based treatment: Monitor renal function regularly with creatinine levels, dose adjustment or alternative medication in case of nephrotoxicity\n\n3. TIER 3 - CONFIRMATION:\n   - Confirmation 1: UTI\n     - Evidence 4: Clinical Success Story\n       Condition: UTI (symptoms similar to the patient's)\n       Intervention: Antibiotics appropriate for UTIs\n       Outcome: Symptom resolution and negative urine culture after completion of treatment\n   - Confirmation 2: Kidney dysfunction due to methotrexate toxicity\n     - Evidence 5: Clinical Success Story\n       Condition: Nephrotoxicity caused by methotrexate\n       Intervention: Renal function monitoring and dose adjustment or alternative medication if needed\n\nIn light of these considerations, it would be appropriate to first test for UTI with a urine culture and sensitivity and initiate antibiotic therapy if positive. Additionally, closely monitor the patient's renal function due to the use of methotrexate as nephrotoxicity is possible.",
                "expected_reasoning": [],
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "unknown",
                "specialty": "general",
                "score": 18.665079365079364,
                "correct": false,
                "metrics": {
                  "reasoning_depth": 0.06999999999999999,
                  "medical_accuracy": 0.32142857142857145,
                  "clinical_workflow": 0.1111111111111111,
                  "specialty_knowledge": 0.4
                },
                "response": " The National Institute for Health and Care Excellence (NICE), also known as the National Institute for Health and Clinical Excellence, is an independent organization responsible for providing national guidance and advice to improve health and social care in England. They produce evidence-based guidance on the appropriate treatment and management of a wide range of clinical conditions, including those related to diabetes and hypertension. The aim is to help healthcare professionals make informed decisions about the most effective and cost-effective interventions for their patients.",
                "expected_reasoning": [],
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "unknown",
                "specialty": "general",
                "score": 13.466666666666665,
                "correct": false,
                "metrics": {
                  "reasoning_depth": 0.06999999999999999,
                  "medical_accuracy": 0.0,
                  "clinical_workflow": 0.3333333333333333,
                  "specialty_knowledge": 0.4
                },
                "response": " Based on the provided information, it seems that the focus is on discussing a medication (Lisinopril) and its use in treating Hyperlipidemia. The discussion does not mention or connect with the presented question about medially directed strabismus (squint).\n\nTo address your question, I would like to provide some general information:\n\nMedial rectus muscle dysfunction is a common cause of esotropia (a type of squint where both eyes turn inwards), which includes damage or weakness of the medial rectus muscle. Some potential causes of this condition include inflammation, muscular imbalance, or injury.\n\nTo diagnose the specific cause and develop an appropriate treatment plan for a patient with esotropia, it is essential to perform a thorough clinical examination, including ophthalmologic evaluation, and consider additional diagnostic tests such as MRI or ultrasound when necessary. Treatment may involve corrective lenses, prism therapy, botulinum toxin injections, or surgery on the affected muscle(s).\n\nIt is crucial always to prioritize patient safety and evidence-based medicine when developing a treatment plan. For this specific condition, it is essential to consult ophthalmologic literature for the most up-to-date and accurate information regarding diagnostic evaluation and treatment options.",
                "expected_reasoning": [],
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "unknown",
                "specialty": "general",
                "score": 29.804575163398695,
                "correct": false,
                "metrics": {
                  "reasoning_depth": 0.37999999999999995,
                  "medical_accuracy": 0.27941176470588236,
                  "clinical_workflow": 0.1111111111111111,
                  "specialty_knowledge": 0.4
                },
                "response": " Based on the provided information, I am a hierarchical diagnostic reasoning assistant that follows clinical decision-making patterns. The pattern recognition identified Lisinopril (an ACE inhibitor) as a drug of interest, and it was noted that Lisinopril is used for various clinical indications such as hypertension, heart failure, post-MI, and diabetic nephropathy.\n\nIn the hypothesis testing phase, I cross-referenced multiple medical sources, including RENAAL, IDNT, AASK, and KDIGO guidelines. These guidelines consistently recommended ACE inhibitors or ARBs as the preferred first-line therapy for chronic kidney disease due to their significant improvements in patient outcomes, including reduced mortality and cardiovascular events.\n\nIn the confirmation phase, I integrated all available information and provided detailed evidence synthesis and confidence assessment. The supportive evidence demonstrated renal protection, aligning with findings from major clinical trials like the RENAAL study, which supports current clinical practice.\n\nHowever, the question asked about an antiepileptic drug associated with congenital malformation when used in pregnant women, not an ACE inhibitor like Lisinopril. I apologize for any confusion this may have caused and will focus on the correct question in future responses.",
                "expected_reasoning": [],
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "unknown",
                "specialty": "general",
                "score": 35.333333333333336,
                "correct": false,
                "metrics": {
                  "reasoning_depth": 0.16999999999999998,
                  "medical_accuracy": 0.24,
                  "clinical_workflow": 0.6666666666666666,
                  "specialty_knowledge": 0.8
                },
                "response": " Based on the provided information, it appears that you are presenting multiple cases of Chronic Kidney Disease (CKD) for which the first-line evidence-based treatment recommended in major international guidelines is Angiotensin-Converting Enzyme inhibitors (ACE inhibitors) or Angiotensin Receptor Blockers (ARBs). These medications help slow the progression of CKD, reduce proteinuria, and provide cardiovascular protection.\n\nTo confirm the diagnosis and treatment plan for a specific patient, more comprehensive clinical evaluation would be necessary, including:\n\n1. Detailed medical history\n2. Physical examination\n3. Laboratory tests (e.g., blood urea nitrogen, serum creatinine, urinalysis)\n4. Imaging studies (e.g., ultrasound, CT scan)\n5. Biopsy in some cases\n\nOnce the diagnosis is confirmed, the appropriate evidence-based treatment plan can be initiated and monitored for effectiveness and potential side effects.\n\nRegarding your question about the anatomical snuffbox, it is a depression on the back of the hand that contains the extensor pollicis brevis, abductor pollicis longus, and extensor pollicis longus muscles. It is found between the tendons of these three muscles in the dorsal aspect of the hand.",
                "expected_reasoning": [],
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "unknown",
                "specialty": "general",
                "score": 15.0,
                "correct": false,
                "metrics": {
                  "reasoning_depth": 0.0,
                  "medical_accuracy": 0.5,
                  "clinical_workflow": 0.0,
                  "specialty_knowledge": 0.0
                },
                "response": " The magnitude of an action potential is primarily determined by three factors:\n\n1. Membrane Resting Potential: This sets the baseline for the action potential, typically -70mV for many excitable cells.\n2. Depolarization Rate: The rate at which the membrane potential rises from the resting potential towards 0mV is crucial in determining the amplitude of the action potential.\n3. Repolarization Kinetics: The speed at which the membrane returns to its resting potential after the action potential has been triggered plays a significant role in shaping the overall magnitude of the action potential.\n\nIn the context of therapeutic interventions, medications like ACE inhibitors or ARBs can influence these factors by modulating ion channel activity and intracellular signaling pathways, ultimately affecting the action potential in targeted cells.",
                "expected_reasoning": [],
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "unknown",
                "specialty": "general",
                "score": 49.91111111111111,
                "correct": false,
                "metrics": {
                  "reasoning_depth": 0.52,
                  "medical_accuracy": 0.3333333333333333,
                  "clinical_workflow": 0.5555555555555556,
                  "specialty_knowledge": 0.8
                },
                "response": " Based on the presented information and hierarchical diagnostic reasoning, we can make the following diagnosis:\n\nThe patient's symptoms of decreased urine output, generalized edema, and elevated creatinine levels suggest a possible worsening of her diabetic nephropathy. Lisinopril is known to have beneficial effects on diabetic nephropathy by reducing proteinuria and stabilizing creatinine levels as shown in multiple clinical success stories. However, the patient's current presentation indicates a deterioration in renal function.\n\nIn Tier 1 - Pattern Recognition, we identified that Lisinopril is primarily used for the treatment of hypertension, heart failure, post-MI, and diabetic nephropathy. In Tier 2 - Hypothesis Testing, we focused on first-line evidence-based treatments for essential hypertension, which included ACE inhibitors or ARBs like Lisinopril. In Tier 3 - Confirmation, we presented clinical success stories demonstrating the beneficial effects of ACE inhibitor therapy on diabetic nephropathy, including proteinuria reduction and stable creatinine levels over time. However, in this case, the patient's presentation suggests a worsening of renal function, which is not consistent with the expected outcomes from Lisinopril treatment for diabetic nephropathy.\n\nTherefore, it is essential to consider alternative explanations and adjust the treatment plan accordingly. Some possible causes of the patient's symptoms could be:\n\n1. ACE inhibitor-induced renal dysfunction: Although rare, Lisinopril can cause acute renal failure in some cases, especially when used concurrently with other nephrotoxic agents or in patients with reduced renal function at baseline.\n2. Worsening of diabetic nephropathy: Despite the beneficial effects of ACE inhibitors on diabetic nephropathy, they may not always prevent disease progression, especially if not used appropriately or combined with poor glycemic control.\n3. Other causes of renal dysfunction: Various conditions can cause renal dysfunction, such as volume depletion, prerenal azotemia, acute tubular necrosis, and post-renal obstruction. These should be investigated to rule out other potential causes.\n\nFurther investigation, including a thorough physical examination, laboratory tests, and imaging studies, will help determine the underlying cause of the patient's symptoms and guide appropriate management decisions. It is crucial to prioritize patient safety and evidence-based medicine in this situation.",
                "expected_reasoning": [],
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "unknown",
                "specialty": "general",
                "score": 32.388888888888886,
                "correct": false,
                "metrics": {
                  "reasoning_depth": 0.19999999999999998,
                  "medical_accuracy": 0.25,
                  "clinical_workflow": 0.4444444444444444,
                  "specialty_knowledge": 0.8
                },
                "response": " Based on the presented symptoms, it appears that the patient might be experiencing depression or anxiety, possibly due to stressors such as financial problems at home and academic difficulties. Given the age of the patient, it's also important to rule out any potential organic causes for these symptoms.\n\nNext steps in management would include:\n\n1. Psychological evaluation: To assess the severity of the depression or anxiety and rule out other mental health conditions. This evaluation should be conducted by a qualified mental health professional.\n2. Family support and counseling: Addressing the family conflict may help alleviate some of the patient's stress. Family therapy could be beneficial in this case.\n3. Academic support: Connecting the patient with school resources, such as a guidance counselor or tutoring services, to help manage academic difficulties.\n4. Lifestyle modifications: Encourage regular physical activity, such as walking or low-impact exercises, and a balanced diet. Additionally, limiting alcohol consumption is recommended.\n5. Monitor for suicidal ideation: Given the patient's statement about thoughts of ending his life, it is crucial to closely monitor him for any signs of increased risk or intent. This may involve regular follow-ups with both the primary care physician and a mental health professional.\n6. Medication (if necessary): If the depression or anxiety is severe enough to interfere significantly with the patient's daily functioning, medication may be considered as an additional treatment option. The choice of medication would depend on the specific diagnosis and should be made in consultation with a mental health professional.\n7. Routine follow-ups: Regular follow-ups with both the primary care physician and mental health professional are essential to monitor the patient's progress, adjust treatments as needed, and ensure safety.",
                "expected_reasoning": [],
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "unknown",
                "specialty": "general",
                "score": 50.488888888888894,
                "correct": false,
                "metrics": {
                  "reasoning_depth": 0.13999999999999999,
                  "medical_accuracy": 1.0,
                  "clinical_workflow": 0.4444444444444444,
                  "specialty_knowledge": 0.6
                },
                "response": " Based on the provided information, the patient presented with a T-score of -1.5 at the femur in a DEXA scan, which indicates osteopenia. The strongest predisposing factor for osteopenia can be identified by considering the patterns and clinical guidelines related to bone health.\n\nPattern 1: Age-related Bone Loss\nClinical Considerations: Age is one of the most significant factors contributing to age-related bone loss, as women experience an accelerated rate of bone loss after menopause.\n\nPattern 2: Gender-Related Bone Loss\nClinical Considerations: Women have a lower peak bone mass and faster bone loss after menopause compared to men.\n\nPattern 3: Family History\nClinical Considerations: A family history of osteoporosis or osteopenia can increase an individual's risk for these conditions.\n\nPattern 4: Nutritional Deficiencies\nClinical Considerations: Inadequate intake of calcium, vitamin D, and other essential nutrients can contribute to the development of osteopenia and osteoporosis.\n\nPattern 5: Low Physical Activity\nClinical Considerations: A sedentary lifestyle or low levels of physical activity can increase an individual's risk for developing osteopenia.\n\nPattern 6: Medications\nClinical Considerations: Certain medications, such as glucocorticoids and certain anticonvulsants, can increase the risk of osteoporosis and osteopenia.\n\nPattern 7: Smoking and Alcohol Consumption\nClinical Considerations: Both smoking and excessive alcohol consumption can contribute to bone loss and increase the risk for osteopenia and osteoporosis.\n\nFor this patient, the strongest predisposing factor for osteopenia is age-related bone loss due to her being a 66-year-old woman (Pattern 1). However, it's essential to consider other factors such as family history, nutritional status, physical activity levels, and medication use to confirm the diagnosis and develop an appropriate treatment plan.",
                "expected_reasoning": [],
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              }
            ],
            "status": "completed"
          },
          "evaluation_time_seconds": 27.809919,
          "gpu_stats": {
            "allocated_gb": 0.18,
            "reserved_gb": 0.21,
            "total_gb": 23.64,
            "utilization_percent": 0.8
          }
        }
      },
      "end_time": "2025-06-20T01:42:42.139433"
    },
    "pubmedqa": {
      "benchmark_name": "pubmedqa",
      "start_time": "2025-06-20T01:42:42.142008",
      "models": {
        "hierarchical_system": {
          "results": {
            "model_name": "unknown_model",
            "benchmark_name": "pubmedqa",
            "evaluation_time": 30.688257217407227,
            "total_questions": 10,
            "successful_evaluations": 10,
            "metrics": {
              "total_questions": 10,
              "average_score": 28.163728222996518,
              "accuracy": 10.0,
              "correct_answers": 1,
              "benchmark_name": "pubmedqa"
            },
            "individual_results": [
              {
                "question_id": "pubmedqa_0008",
                "study_type": "meta_analysis",
                "score": 17.34285714285714,
                "correct": false,
                "metrics": {
                  "answer_accuracy": 0.0,
                  "evidence_synthesis": 0.4704761904761905,
                  "research_quality": 0.0,
                  "citation_usage": 0.32285714285714284
                },
                "response": " Based on the pattern recognition, hypothesis testing, and confirmation tiers, it can be concluded that Atorvastatin is primarily used to treat Hyperlipidemia for both primary and secondary cardiovascular prevention. The primary therapeutic benefit of Atorvastatin is a reduction in LDL cholesterol levels by 40-50%.\n\nIn the hypothesis testing tier, it was determined that high-intensity statin therapy, such as Atorvastatin, is the first-line evidence-based treatment for Hyperlipidemia. This conclusion was supported by several clinical success stories demonstrating a significant reduction in LDL cholesterol levels and no cardiovascular events at 2-year follow-ups.\n\nRegarding your question about whether statins reduce cardiovascular mortality in primary prevention, the answer is yes. While the exact reduction in mortality may vary among individuals, numerous clinical trials such as the JUPITER study have demonstrated a significant reduction in cardiovascular events and mortality with the use of statins for primary prevention in high-risk patients. However, it's important to note that individual responses can differ, so it is essential to consider patient-specific factors when making treatment decisions. Always consult with a healthcare professional for personalized medical advice.",
                "expected_answer": "yes",
                "expected_explanation": "Yes, statins significantly reduce cardiovascular mortality in primary prevention. Meta-analyses show 25-30% reduction in major cardiovascular events.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "pubmedqa_0009",
                "study_type": "clinical_trial",
                "score": 15.771428571428572,
                "correct": false,
                "metrics": {
                  "answer_accuracy": 0.0,
                  "evidence_synthesis": 0.38476190476190475,
                  "research_quality": 0.1,
                  "citation_usage": 0.22285714285714286
                },
                "response": " Based on the pattern recognition, hypothesis testing, and confirmation tiers of diagnostic reasoning, it appears that the patient may be receiving treatment for Acute Coronary Syndrome (ACS) with dual antiplatelet therapy consisting of aspirin and a P2Y12 inhibitor. This therapy is effective in reducing recurrent Myocardial Infarction (MI) by 20%, as proven in the CURE trial.\n\nRegarding your question about aspirin's effectiveness for stroke prevention in atrial fibrillation, the answer is affirmative. Aspirin has been shown to reduce the risk of stroke in patients with atrial fibrillation when used appropriately and under medical supervision. This is consistent with evidence from numerous clinical trials such as the Stroke Prevention Trial in Atrial Fibrillation (SPAF) and the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) trial. However, it's important to note that the optimal dosage and duration of aspirin therapy for stroke prevention in atrial fibrillation may vary depending on individual patient factors and underlying risk profile. Always consult with a healthcare professional before making any changes to a patient's treatment plan.",
                "expected_answer": "maybe",
                "expected_explanation": "Aspirin provides some stroke prevention in atrial fibrillation but is less effective than oral anticoagulants.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "pubmedqa_0006",
                "study_type": "systematic_review",
                "score": 25.44547038327526,
                "correct": false,
                "metrics": {
                  "answer_accuracy": 0.0,
                  "evidence_synthesis": 0.5678571428571428,
                  "research_quality": 0.3,
                  "citation_usage": 0.24097560975609758
                },
                "response": " To address your question, let's go through the three-tier reasoning process:\n\nTIER 1 - PATTERN RECOGNITION:\nPattern: Vitamin D supplementation\nClinical Indications: Prevention of fractures in elderly, Treatment of vitamin D deficiency, Supportive therapy for osteoporosis\n\nTIER 2 - HYPOTHESIS TESTING:\nHypothesis: Clinical Condition: Fracture prevention in the elderly\nFirst-line Evidence-based Treatment: Vitamin D supplementation\nMechanism of Action: Maintains calcium homeostasis, promotes bone mineralization, and improves muscle function\nProven Clinical Benefits:\n- Reduces fracture risk by 10-25% in elderly individuals with vitamin D deficiency or insufficiency\n- Improves bone mineral density (BMD) in postmenopausal women\n- Reduces falls risk and improves muscle function in the elderly\n\nTIER 3 - CONFIRMATION:\nEvidence: Supporting Evidence: Meta-analysis of randomized controlled trials (RCTs) demonstrates a reduced fracture risk with vitamin D supplementation\nClinical Significance: This evidence supports the use of vitamin D supplementation in preventing fractures in elderly individuals with vitamin D deficiency or insufficiency, as it reduces the risk by 10-25%. However, it's important to note that the optimal dosage for fracture prevention remains controversial and should be individualized based on a patient's specific needs.",
                "expected_answer": "maybe",
                "expected_explanation": "Vitamin D supplementation may prevent fractures in elderly, particularly when combined with calcium and in vitamin D deficient populations.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "pubmedqa_0007",
                "study_type": "comparative_study",
                "score": 61.60952380952382,
                "correct": true,
                "metrics": {
                  "answer_accuracy": 1.0,
                  "evidence_synthesis": 0.46031746031746035,
                  "research_quality": 0.1,
                  "citation_usage": 0.5800000000000001
                },
                "response": " Based on the pattern recognition of therapeutic drugs, we have identified that the patient is likely being treated with an ACE Inhibitor. Given the repetition in this specific pattern, it's reasonable to assume that the ACE inhibitor in question is either Lisinopril, Enalapril, or Ramipril.\n\nIn the hypothesis testing phase, we cross-referenced multiple medical sources such as RENAAL, IDNT, AASK, and KDIGO guidelines which support the use of ACE inhibitors or ARBs as the preferred first-line therapy for Chronic Kidney Disease due to robust clinical trial evidence demonstrating significant improvements in patient outcomes including reduced mortality and cardiovascular protection.\n\nIn the confirmation phase, we integrated all available information from clinical success stories, where the use of ACE inhibitors (specifically Lisinopril) as first-line therapy led to excellent blood pressure control and cardiovascular protection, which is consistent with findings from the Heart Outcomes Prevention Evaluation (HOPE) trial.\n\nIn response to your question about whether ACE inhibitors are superior to ARBs for heart failure, it's important to note that both classes of drugs have similar benefits in heart failure treatment but may vary based on individual patient factors such as tolerability and comorbidities. Therefore, the choice between an ACE inhibitor and an ARB should be individualized based on a comprehensive evaluation of the patient's medical history and current condition.",
                "expected_answer": "no",
                "expected_explanation": "ACE inhibitors are not superior to ARBs for heart failure. Both show similar mortality benefits with comparable efficacy.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "pubmedqa_0008",
                "study_type": "meta_analysis",
                "score": 14.771428571428572,
                "correct": false,
                "metrics": {
                  "answer_accuracy": 0.0,
                  "evidence_synthesis": 0.38476190476190475,
                  "research_quality": 0.0,
                  "citation_usage": 0.32285714285714284
                },
                "response": " Based on the presented pattern recognition, hypothesis testing, and confirmation of evidence, it can be concluded that Atorvastatin, a high-intensity statin therapy, is an effective treatment for Hyperlipidemia. The primary therapeutic benefit of Atorvastatin is reducing LDL cholesterol levels by 30-50%. This reduction in LDL cholesterol can lead to a 25-30% decrease in cardiovascular events and potentially contribute to mortality benefits, although specifics may vary depending on the patient's risk profile.\n\nRegarding your question about whether statins reduce cardiovascular mortality in primary prevention, evidence from clinical studies like PROVE-IT and TNT trials supports a reduction in cardiovascular events with statin therapy in high-risk patients. However, the exact impact on cardiovascular mortality in primary prevention may depend on factors such as the patient's individual risk profile and adherence to treatment. It is essential to consider these factors when making personalized treatment recommendations for each patient.",
                "expected_answer": "yes",
                "expected_explanation": "Yes, statins significantly reduce cardiovascular mortality in primary prevention. Meta-analyses show 25-30% reduction in major cardiovascular events.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "pubmedqa_0009",
                "study_type": "clinical_trial",
                "score": 18.085714285714282,
                "correct": false,
                "metrics": {
                  "answer_accuracy": 0.0,
                  "evidence_synthesis": 0.4380952380952381,
                  "research_quality": 0.1,
                  "citation_usage": 0.29428571428571426
                },
                "response": " Based on the pattern recognition, hypothesis testing, and confirmation tiers, it appears that the medications being discussed are all Antiplatelet Agents primarily used for clinical conditions such as Acute Coronary Syndrome (ACS). The first-line evidence-based treatment for ACS is Dual antiplatelet therapy (Aspirin + P2Y12 inhibitor), which has been shown to reduce recurrent myocardial infarction (MI) by 20% and provide cardiovascular benefits. However, your question pertains to the use of aspirin for stroke prevention in atrial fibrillation.\n\nIn the case of atrial fibrillation, the standard therapy for stroke prevention is usually Vitamin K antagonists (such as warfarin) or Novel oral anticoagulants (NOACs). Aspirin can also be used but it's generally considered secondary prevention in this context. The CHA2DS2-VASc score is used to assess the risk of stroke in atrial fibrillation patients, and those with a score of 2 or more are usually candidates for anticoagulation therapy. Aspirin may be considered in certain situations where anticoagulation is contraindicated or not tolerated.\n\nIn summary, while aspirin is effective as an antiplatelet agent for conditions such as ACS, its role in stroke prevention in atrial fibrillation is typically secondary to anticoagulant therapy. Always consult the most recent evidence and guidelines when making treatment decisions.",
                "expected_answer": "maybe",
                "expected_explanation": "Aspirin provides some stroke prevention in atrial fibrillation but is less effective than oral anticoagulants.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "pubmedqa_0006",
                "study_type": "systematic_review",
                "score": 38.73466898954704,
                "correct": false,
                "metrics": {
                  "answer_accuracy": 0.0,
                  "evidence_synthesis": 0.7392857142857142,
                  "research_quality": 0.7,
                  "citation_usage": 0.255609756097561
                },
                "response": " To answer your question, let us follow the hierarchical diagnostic reasoning process:\n\nTIER 1 - PATTERN RECOGNITION:\nIdentify relevant medical patterns and generate initial differential diagnoses.\nFocus on rapid pattern recognition and clinical intuition.\nUse the comprehensive knowledge base for pattern matching.\n\nPattern: Drug Intervention with Vitamin D\n\nClinical Indication: Prevention of Fractures in Elderly\n\nTIER 2 - HYPOTHESIS TESTING:\nTest hypotheses using evidence-based reasoning chains.\nApply systematic diagnostic reasoning and knowledge graph connections.\nCross-reference multiple medical sources for hypothesis validation.\n\nHypothesis: Clinical Condition: Prevention of Fractures in Elderly\n\nFIRST-LINE EVIDENCE-BASED TREATMENT: Vitamin D supplementation\n\nMechanism of Action: Supports bone health by promoting calcium absorption, maintaining serum calcium levels, and reducing parathyroid hormone secretion.\n\nProven Clinical Benefits:\n\u2022 Reduces the risk of hip fractures in elderly women with low vitamin D levels\n\u2022 May reduce the risk of other types of fractures in elderly individuals with or without low vitamin D levels, but the evidence is less clear\n\nTIER 3 - CONFIRMATION:\nConfirm diagnosis with comprehensive clinical evidence.\nIntegrate all available information for final diagnostic confirmation.\nProvide detailed evidence synthesis and confidence assessment.\n\nEvidence: Supporting Evidence: The Women's Health Initiative (WHI) randomized controlled trial\n\nClinical Significance: The WHI trial showed no significant reduction in the risk of total fractures, hip fractures, or any other specific type of fracture with calcium and vitamin D supplementation. However, a subgroup analysis suggested that vitamin D supplementation may reduce the risk of nonvertebral fractures in women with low baseline vitamin D levels.\n\nEvidence: Supporting Evidence: The Vitamin D and Fracture Prevention (VDP) randomized controlled trial\n\nClinical Significance: The VDP trial found that vitamin D supplementation reduced the risk of nonvertebral fractures in elderly individuals with low vitamin D levels, but it had no significant effect on the risk of hip or vertebral fractures.\n\nEvidence: Supporting Evidence: A systematic review and meta-analysis by Bischoff-Ferrari et al. (2019)\n\nClinical Significance: This study found that vitamin D supplementation reduced the risk of hip fracture in elderly women with low vitamin D levels, but the evidence was less clear for other types of fractures. The authors concluded that further research is needed to clarify the role of vitamin D in fracture prevention.\n\nQuestion: Based on the evidence, can we confidently state that vitamin D supplementation prevents fractures in elderly?\n\nHierarchical Diagnostic Response: While there is some evidence suggesting that vitamin D supplementation may reduce the risk of fractures in certain subgroups of elderly individuals with low vitamin D levels, the overall evidence is less clear. Therefore, we cannot confidently state that vitamin D supplementation prevents fractures in all elderly individuals. It is important to consider individual patient factors and discuss the risks and benefits of vitamin D supplementation with a healthcare provider.",
                "expected_answer": "maybe",
                "expected_explanation": "Vitamin D supplementation may prevent fractures in elderly, particularly when combined with calcium and in vitamin D deficient populations.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "pubmedqa_0007",
                "study_type": "comparative_study",
                "score": 57.990476190476194,
                "correct": false,
                "metrics": {
                  "answer_accuracy": 1.0,
                  "evidence_synthesis": 0.41587301587301584,
                  "research_quality": 0.0,
                  "citation_usage": 0.5514285714285714
                },
                "response": " Based on the current evidence available, it appears that both ACE inhibitors and Angiotensin Receptor Blockers (ARBs) have demonstrated efficacy in treating chronic kidney disease and heart failure. However, ACE inhibitors are often recommended as a first-line therapy due to robust clinical trial evidence demonstrating significant improvements in patient outcomes, including reduced mortality and cardiovascular events. This recommendation is consistent with guidelines from the RENAAL, IDNT, AASK, and KDIGO studies.\n\nThe superiority of ACE inhibitors over ARBs for heart failure may depend on specific patient factors such as comorbidities, tolerability to side effects, and cost. It's essential to consider individual patient circumstances before making a definitive choice between the two drug classes.\n\nFor detailed information, you can refer to the following sources:\n- The Heart Failure Society of America (HFSA) guidelines for the diagnosis and treatment of heart failure: <https://academic.oup.com/eurheartj/article/38/15/2059/5747467>\n- The European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of acute and chronic heart failure: <https://doi.org/10.1093/eurheartj/ehaa368>\n\nIn this response, I have prioritized patient safety and evidence-based medicine, leveraged comprehensive medical knowledge for detailed diagnostic reasoning, and followed the three-tier reasoning pattern: Pattern Recognition (identifying ACE inhibitors as a common therapeutic class), Hypothesis Testing (cross-referencing multiple medical sources to support the preferred first-line therapy for chronic kidney disease), and Confirmation (providing detailed evidence synthesis and confidence assessment based on clinical success stories).",
                "expected_answer": "no",
                "expected_explanation": "ACE inhibitors are not superior to ARBs for heart failure. Both show similar mortality benefits with comparable efficacy.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "pubmedqa_0008",
                "study_type": "meta_analysis",
                "score": 13.428571428571429,
                "correct": false,
                "metrics": {
                  "answer_accuracy": 0.0,
                  "evidence_synthesis": 0.3257142857142857,
                  "research_quality": 0.0,
                  "citation_usage": 0.3657142857142857
                },
                "response": " Based on the pattern recognition, hypothesis testing, and confirmation stages, it is highly likely that the patient has hyperlipidemia. The primary therapeutic benefit of Atorvastatin, a statin drug, is its ability to reduce LDL cholesterol levels by 30-50%. This aligns with the first-line evidence-based treatment for hyperlipidemia, which is high-intensity statin therapy.\n\nThe confirmation stage involved integrating multiple clinical success stories where patients with hyperlipidemia and high cardiovascular risk were treated with high-intensity statin therapy (Atorvastatin 80mg). These cases showed a significant reduction in LDL cholesterol levels (180 mg/dL to 65 mg/dL) and no cardiovascular events at the 2-year follow-up. This aligns with the proven clinical benefits of statins, which include reducing cardiovascular events by 25-30% and showing a mortality benefit in certain populations.\n\nRegarding your question about whether statins reduce cardiovascular mortality in primary prevention, yes, they do. Statins have been shown to reduce cardiovascular mortality in both primary and secondary prevention settings. However, the exact reduction percentage may vary depending on factors such as the individual's risk level and the specific statin used. It is crucial to consult with a healthcare professional for personalized medical advice.",
                "expected_answer": "yes",
                "expected_explanation": "Yes, statins significantly reduce cardiovascular mortality in primary prevention. Meta-analyses show 25-30% reduction in major cardiovascular events.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "pubmedqa_0009",
                "study_type": "clinical_trial",
                "score": 18.457142857142856,
                "correct": false,
                "metrics": {
                  "answer_accuracy": 0.0,
                  "evidence_synthesis": 0.4647619047619047,
                  "research_quality": 0.1,
                  "citation_usage": 0.25142857142857145
                },
                "response": " Based on the pattern recognition, hypothesis testing, and confirmation tiers of reasoning:\n\nThe identified patterns suggest that the patient may be receiving antiplatelet therapy, primarily Aspirin or other P2Y12 inhibitors. This is consistent with a clinical application for Acute Coronary Syndrome (ACS) prevention or management.\n\nHypothesis testing reveals that dual antiplatelet therapy (Aspirin + P2Y12 inhibitor) is the first-line evidence-based treatment for ACS, as it reduces recurrent Myocardial Infarction (MI) by 20% and provides cardiovascular protection.\n\nTo confirm the diagnosis, we can integrate all available information from the patient's history, physical examination, and lab results. If these findings align with the criteria for ACS, then it is likely that the patient has been prescribed antiplatelet therapy for this condition.\n\nRegarding stroke prevention in atrial fibrillation (AF), aspirin can be effective but may not be the first-line treatment option. Direct oral anticoagulants (DOACs) are often considered as the first choice due to their superior efficacy and safety profile compared to aspirin for stroke prevention in AF patients without significant bleeding risk. However, it's essential to discuss specific cases with a healthcare provider to determine the best course of action based on individual patient factors.",
                "expected_answer": "maybe",
                "expected_explanation": "Aspirin provides some stroke prevention in atrial fibrillation but is less effective than oral anticoagulants.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              }
            ],
            "status": "completed"
          },
          "evaluation_time_seconds": 30.691249,
          "gpu_stats": {
            "allocated_gb": 0.18,
            "reserved_gb": 0.21,
            "total_gb": 23.64,
            "utilization_percent": 0.8
          }
        }
      },
      "end_time": "2025-06-20T01:43:13.055861"
    },
    "msmarco": {
      "benchmark_name": "msmarco",
      "start_time": "2025-06-20T01:43:13.058795",
      "models": {
        "hierarchical_system": {
          "results": {
            "model_name": "unknown_model",
            "benchmark_name": "msmarco",
            "evaluation_time": 20.037009716033936,
            "total_questions": 10,
            "successful_evaluations": 10,
            "metrics": {
              "total_questions": 10,
              "average_score": 0.0,
              "accuracy": 0.0,
              "correct_answers": 0,
              "benchmark_name": "msmarco"
            },
            "individual_results": [
              {
                "question_id": "msmarco_0005",
                "query": "symptoms of diabetes mellitus",
                "query_type": "symptom_lookup",
                "score": 0.0,
                "correct": false,
                "metrics": {
                  "precision_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "recall_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "ndcg_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "map": 0.0,
                  "mrr": 0.0
                },
                "retrieved_count": 10,
                "relevant_count": 2,
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "msmarco_0006",
                "query": "treatment for hypertension first line",
                "query_type": "treatment_lookup",
                "score": 0.0,
                "correct": false,
                "metrics": {
                  "precision_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "recall_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "ndcg_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "map": 0.0,
                  "mrr": 0.0
                },
                "retrieved_count": 10,
                "relevant_count": 2,
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "msmarco_0007",
                "query": "myocardial infarction diagnosis criteria",
                "query_type": "diagnostic_criteria",
                "score": 0.0,
                "correct": false,
                "metrics": {
                  "precision_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "recall_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "ndcg_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "map": 0.0,
                  "mrr": 0.0
                },
                "retrieved_count": 10,
                "relevant_count": 2,
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "msmarco_0008",
                "query": "side effects of statins",
                "query_type": "adverse_effects",
                "score": 0.0,
                "correct": false,
                "metrics": {
                  "precision_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "recall_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "ndcg_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "map": 0.0,
                  "mrr": 0.0
                },
                "retrieved_count": 10,
                "relevant_count": 2,
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "msmarco_0009",
                "query": "heart failure classification NYHA",
                "query_type": "classification",
                "score": 0.0,
                "correct": false,
                "metrics": {
                  "precision_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "recall_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "ndcg_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "map": 0.0,
                  "mrr": 0.0
                },
                "retrieved_count": 10,
                "relevant_count": 4,
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "msmarco_0005",
                "query": "symptoms of diabetes mellitus",
                "query_type": "symptom_lookup",
                "score": 0.0,
                "correct": false,
                "metrics": {
                  "precision_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "recall_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "ndcg_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "map": 0.0,
                  "mrr": 0.0
                },
                "retrieved_count": 10,
                "relevant_count": 2,
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "msmarco_0006",
                "query": "treatment for hypertension first line",
                "query_type": "treatment_lookup",
                "score": 0.0,
                "correct": false,
                "metrics": {
                  "precision_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "recall_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "ndcg_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "map": 0.0,
                  "mrr": 0.0
                },
                "retrieved_count": 10,
                "relevant_count": 2,
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "msmarco_0007",
                "query": "myocardial infarction diagnosis criteria",
                "query_type": "diagnostic_criteria",
                "score": 0.0,
                "correct": false,
                "metrics": {
                  "precision_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "recall_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "ndcg_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "map": 0.0,
                  "mrr": 0.0
                },
                "retrieved_count": 10,
                "relevant_count": 2,
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "msmarco_0008",
                "query": "side effects of statins",
                "query_type": "adverse_effects",
                "score": 0.0,
                "correct": false,
                "metrics": {
                  "precision_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "recall_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "ndcg_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "map": 0.0,
                  "mrr": 0.0
                },
                "retrieved_count": 10,
                "relevant_count": 2,
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "msmarco_0009",
                "query": "heart failure classification NYHA",
                "query_type": "classification",
                "score": 0.0,
                "correct": false,
                "metrics": {
                  "precision_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "recall_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "ndcg_at_k": {
                    "1": 0.0,
                    "3": 0.0,
                    "5": 0.0,
                    "10": 0.0
                  },
                  "map": 0.0,
                  "mrr": 0.0
                },
                "retrieved_count": 10,
                "relevant_count": 4,
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              }
            ],
            "status": "completed"
          },
          "evaluation_time_seconds": 20.041043,
          "gpu_stats": {
            "allocated_gb": 0.18,
            "reserved_gb": 0.2,
            "total_gb": 23.64,
            "utilization_percent": 0.8
          }
        }
      },
      "end_time": "2025-06-20T01:43:33.309295"
    }
  }
}